Changing sero-epidemiology of hepatitis A in Asia Pacific countries: A systematic review

Gripenberg, Marissa; D’Cor, Naveena Aloysia; L’Azou, Maïna; Marsh, Grenville; Druelles, Sophie; Nealon, Joshua

doi:10.1016/j.ijid.2017.12.021

Cited by 27 publications

(29 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In terms of the epidemiology of HAV infection in Latin America, most countries in this region appear to be in the process of transitioning to a lower endemicity level. Worldwide, many countries have already shifted to lowintermediate levels of endemicity and are trending toward low levels, while some countries continue to have high rates of transmission [2,13,14,84,85]. With decreasing incidences of HAV infection in early life, an increasing number of adolescents and adults are susceptible to infection from a variety of factors such as contaminated food, contact with an infectious person, poor hygiene, water treatment system failures, travel to rural areas in the same country, and travel to other countries with higher endemicity levels [2].…”

Section: Expert Opinionmentioning

confidence: 99%

Hepatitis A epidemiology in Latin American countries: a 2020 view from a systematic literature review

Andani

Elten²,

Bunge³

et al. 2020

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction: The World Health Organization recommends vaccination against hepatitis A virus (HAV) for children aged 1 year and older in areas where endemicity has shifted from high to intermediate. There are no recent comprehensive reviews of the epidemiology of HAV infection in Latin America, but seroprevalence and socioeconomic data suggest that, with improved clean water and sanitation systems, countries are transitioning to intermediate endemicity. Areas covered: We conducted a systematic literature review of the epidemiology of HAV infection in 25 countries in the Latin American region, which included gray literature. We compiled data on HAV incidence and prevalence, including the identification of epidemiological changes observed in countries that established pediatric HAV vaccination programs. Expert opinion: We identified 59 relevant articles, including 34 peer-reviewed seroprevalence studies (12 recent studies from Brazil), three incidence studies, and six vaccine impact studies (three from Argentina). Based on the estimated age at midpoint of population immunity in each country, most have a high-intermediate, intermediate, or low-intermediate level of HAV endemicity, suggesting that national childhood immunization may be an appropriate disease prevention strategy. However, recent data were lacking for most countries. Improved data quality and continued epidemiological surveillance are required for this region.

show abstract

Section: Expert Opinionmentioning

confidence: 99%

Hepatitis A epidemiology in Latin American countries: a 2020 view from a systematic literature review

Andani

Elten²,

Bunge³

et al. 2020

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

“… 3 The most obvious decrease was detected in some middle-income countries where the UCVP against HepA was introduced. 4 , 78 , 91 , 95 , 96 , 103 , 104 However, given that younger adults will be much sicker after HAV infection than children, the increase of HAV infection age might initially cause an increase in the number of clinically apparent cases and hospitalization from hepatitis A. In recent years, hepatitis A outbreaks were reported frequently among populations in age groups not covered by the UCVP in Korea.…”

Section: Epidemiological Shift After Hepatitis a Vaccinationmentioning

confidence: 99%

“…2 Hepatitis A vaccine (HepA) was first used worldwide in 1992 and its role in hepatitis A control has been proven in many countries. [3][4][5][6] However, more than 7000 persons died from hepatitis A worldwide in 2016. 7 The goal of eliminating viral hepatitis by 2030 was put forward by the World Health Organization (WHO) in 2016, 8 and more efforts should be made to achieve this goal.…”

Section: Introductionmentioning

confidence: 99%

Hepatitis A vaccination

Zhang

2020

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Hepatitis A is an important public health issue worldwide. Hepatitis A vaccine (HepA) was first licensed in 1992. Both inactivated HepA (HepA-I) and live attenuated HepA (HepA-L) are highly immunogenic and well tolerated, and immune protection postvaccination can persist for at least 20 y. HepA is effective for both preexposure and postexposure prophylaxis, especially among children and young adults. The strategy of HepA vaccination varies in different countries and mainly includes vaccination among highrisk populations, regional childhood vaccination and universal childhood vaccination. The incidence of hepatitis A has decreased greatly in many countries in the last 30 y, but hepatitis A outbreaks frequently occur among high-risk populations and those who have not been covered by universal child vaccination programs in recent years. Disease surveillance and serosurveys are suggested to clarify the shift in the epidemiology of hepatitis A. The long-term persistence of immune protection after one dose of HepA should be further studied, as well as the cost-effective evaluation of different strategies of HepA vaccination. Based on this evidence, the recommendation on HepA vaccination should be put forward scientifically and updated in a timely and well-implemented manner.

show abstract

“…Hepatitis A virus (HAV) and hepatitis E virus (HEV) are transmitted from person to person through contaminated food and sometimes through water. The distribution of the virus is closely related to hygiene and sanitation standards . There is a total of 1.4 million reported HAV infections worldwide each year, approximately half of which occur in Asian countries .…”

Section: Introductionmentioning

confidence: 99%

“…The distribution of the virus is closely related to hygiene and sanitation standards. 1,2 There is a total of 1.4 million reported HAV infections worldwide each year, approximately half of which occur in Asian countries. 3,4 In 2005, there were an estimated 20.1 (95% CI: 2.8-37.0) million incident HEV infections worldwide; furthermore, 60.6% of cases occurred in East and Southeast Asia, and these two regions accounted for 64.7% of deaths from HEV infection.…”

Section: Introductionmentioning

confidence: 99%

Changing trends in viral hepatitis mortality in East and Southeast Asia between 1987 and 2015 and its prediction until 2030

Wang

Liu

et al. 2019

Liver International

View full text Add to dashboard Cite

Background & Aims: Trends in long-term mortality rates for viral hepatitis in East andSoutheast Asia have been rarely reported. The aim of our study was to explore the long-term trends in viral hepatitis mortality rates in East and Southeast Asian countries between 1987 and 2015 and provide predictions of mortality to 2030. Methods:We obtained viral hepatitis mortality data from the WHO Mortality Database for six East and Southeast Asian countries between 1987 and 2015. We produced choropleth maps of viral hepatitis mortality rates in 1987 and 2015 in East and Southeast Asia to illustrate geographic variations. We made predictions of mortality rates for each included country until the year 2030 using a series of joinpoint models.Results: Viral hepatitis mortality rates declined in China (the average annual percent change (AAPC) = −5.1%, 95% CI: −7.5, −2.6), Singapore (AAPC = −5.4%, 95% CI: −7.5, −3.2), and the Philippines (AAPC = −3.4%, 95% CI: −4.9, −1.8). In contrast, Japan, the Republic of Korea, and Malaysia have experienced increasing trends in mortality rates, followed by decreasing trends. Our predictions indicate that all countries will experience slight to moderate downward trends until 2030. Conclusion: Favourable decreasing trends have been noted in East and SoutheastAsian countries, which may not only inform the control and management of viral hepatitis in this region but also guide the prevention of viral hepatitis deaths in another region with a similar viral hepatitis epidemic. K E Y W O R D S East and Southeast Asia, mortality rate, secular trends, viral hepatitis S U PP O RTI N G I N FO R M ATI O N Additional supporting information may be found online in the Supporting Information section. How to cite this article: Wu J, Wang H-L, Liu X, et al. Changing trends in viral hepatitis mortality in East and Southeast Asia between 1987 and 2015 and its prediction until 2030. Liver Int. 2020;40:298-307. https ://doi.

show abstract

Changing sero-epidemiology of hepatitis A in Asia Pacific countries: A systematic review

Cited by 27 publications

References 20 publications

Hepatitis A epidemiology in Latin American countries: a 2020 view from a systematic literature review

Hepatitis A epidemiology in Latin American countries: a 2020 view from a systematic literature review

Hepatitis A vaccination

Changing trends in viral hepatitis mortality in East and Southeast Asia between 1987 and 2015 and its prediction until 2030

Contact Info

Product

Resources

About